Roche Pharmaceutical Development and Sales Overview
Tiragolumab (anti-TIGIT, RG6058, MTIG7192A)
Monoclonal antibody targeting the immune checkpoint inhibitor TIGIT
Indication
Solid tumors
NSCLC
Roche
Relapsed or refractory multiple myeloma (MM)
or r/r B-cell NHL
Phase/study
# of patients
"
Design
Primary endpoint
Status
CT Identifier
Phase I
Phase II
CITYSCAPE
Phase I
N=540
Phase la: Dose escalation and expansion of
tiragolumab
Phase lb: Dose escalation and expansion of
tiragolumab in combination with Tecentriq
and/or other anti-cancer therapies
Safety, tolerability, PK variability and
preliminary efficacy
"
FPI Q2 2016
Data presented at AACR 2020
"
"
N=135
ARM A: Tecentriq plus tiragolumab
ARM B: Tecentriq monotherapy
Overall response rate and progression-free
survival
FPI Q3 2018
Recruitment completed Q2 2019
Data presented at ASCO 2020 and WCLC and
ESMO IO 2021
BTD granted by FDA Q4 2020
Published in Lancet Oncol 2022
Jun;23(6):781-792
ā
N=52
Phase la: Tiragolumab monotherapy
Phase Ib: Tiragolumab plus daratumumab (r/r
MM) or rituximab (r/r NHL)
Safety, tolerability, PK/PD and preliminary
efficacy
FPI Q2 2019
NCT02794571
NCT03563716
NCT04045028
BTD=Breakthrough therapy designation; MM-Multiple myeloma; NSCLC=Non-small cell lung cancer; r/r-Relapsed refractory; NHL-Non-Hodgkin's lymphoma; PK-Pharmacokinetics; PD=Pharmacodynamics; ASCO=American
Society of Clinical Oncology; AACR-American Association for Cancer Research; WCLC=World Conference on Lung Cancer; ESMO IO-European Society for Medical Oncology - Immuno-Oncology
108
OncologyView entire presentation